Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics
Authors:
- 4 January 2013
- journal article
- research article
- Published by Wiley in Brain Pathology
- Vol. 23 (4) , 454-461
Abstract
Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM‐O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM‐Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation‐specific polymerase chain reaction (PCR). GBM‐Os accounted for 11.9% of all GBMs. GBM‐Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM‐Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM‐O appeared to be associated with a younger age at presentation. Among patients with GBM‐O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM‐O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.Keywords
This publication has 32 references indexed in Scilit:
- Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomasInternational Journal of Oncology, 2012
- Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcomeNeuro-Oncology, 2012
- Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO)Brain Tumor Pathology, 2011
- Genetic profile of astrocytic and oligodendroglial gliomasBrain Tumor Pathology, 2011
- Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencingBrain Tumor Pathology, 2011
- IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomasNeuro-Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosisVirchows Archiv, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007